IRD's Quality Score rose 5 points on Fri, Nov 6, to -1. Its price closed above its average of the last 21 days, which is rising (4 chart checks started).
Follow IRD's trial news. Pro members can get an alert when Opus Genetics files news, and see its trials, share raises, and its CEO's filings.
We do the work for you. Every stock is scored and ranked, every 15 seconds while the market is open. Here it's 15 minutes behind. Pro members see it live.
Up 106% in a year while the S&P 500 rose 11%.
“The increase in net loss was primarily due to higher R&D expense, lower license and collaborations revenue, and higher financing costs period over period.”
| Holding it back | Profit turned to a loss |
| Latest filing | 8-K, Oct 21 |
ReportExpected to report Wednesday, before the open. Every 3 months, a company tells everyone how much it sold and earned. It rose after 2 and fell after 2 of its last 4 reports, -0.3% on average. Past reports ›
Tue Nov 10: Guggenheim 3rd Annual Global…Investor conference · date confirmed.
1 more date ahead: the conference, for Pro members.
After its last 4 reports it closed -0.3% on average, higher 2 of 4 times.
The company says its cash lasts into 2029 (8-K, Sep 11).
CEO George Magrath sold 28,258 shares on Nov 3. 21 more insider trades this year.
Decision dates and advisory committee meetings the companies have announced in their filings, soonest first and small companies first.
Poorfor quality, not price, 5 of 14 chart checks firingWhat the Quality Score means
IRD is #60 of 90 by Quality Score.
| Rank | Stock | Quality Score |
|---|---|---|
| 1 | ||
| 2 | ||
| 3 | ||
| Open for its score | ||
| Open for its score | ||
| Open for its score | ||
| Open for its score | ||
| 60 |
Expected to report Wed Nov 11, before the open (in 2 days).
What an earnings report is: every 3 months, a company tells everyone how much it sold and earned. We read the figures, the outlook, and how the stock moved after.
The figures are not read from the release yet.
“The increase in net loss was primarily due to higher R&D expense, lower license and collaborations revenue, and higher financing costs period over period.”
IRD's results filing gives no sales by line in a table we read.
No outlook figures read from this release.
“The increase was primar ily attributable to higher manufacturing and clinical costs associated with the Company's IRD programs, partially offset by lower clinical costs associated with the Phentolamine Ophthalmic Solution 0.75% programs.”
From its results filing (SEC filing · Aug 6)
| Reported | Gap | Reaction | 5 days |
|---|---|---|---|
| Aug 6, 2026 | -1.1% | -1.6% | -0.5% |
| May 12, 2026 | -1.8% | +1.2% | -13.3% |
| Mar 10, 2026 | 0.0% | +1.7% | +8.8% |
Sales grew in three of the last five years, to $14.2M in 2025. It made a profit in one of the six years.
RSI 52.6, MACD above signal, below both averages. Not scored.
5 insiders sold $10.6M across 12 filings in the last 6 months. No open-market buys on record. The newest:
Officers and directors with a Form 4 in the last 12 months.
In ETFs: IRD is under 0.1% of VTI, the most of the 24 funds Breakaway covers, by their holdings as filed for Jun 30, 2026.
Opus Genetics Inc is a clinical-stage ophthalmic biopharmaceutical company developing therapies to treat patients with inherited retinal diseases (IRDs) and therapies to treat patients with other retinal and refractive disorders. The pipeline includes seven adeno-associated virus (AAV)-based programs, led by OPGx-LCA5 for LCA5-related mutations and OPGx-BEST1 for BEST1-related retinal degeneration, with additional candidates targeting RHO, CNGB1, RDH12, NMNAT1, and MERTK. The company operates in one operating segment, which is the business of developing products related to vision performance and health.
“We and our development partners face competition from both branded and generic pharmaceutical companies as well as products that are currently in development.”
IRD scores -1 today, which Breakaway calls Poor. It is #60 of 90 in Pharma by Quality Score, with 5 of 14 chart checks firing. Up 106% in a year while the S&P 500 rose 11%. Shares: 50.7% more than a year ago (to Jun 30). Breakaway does not say whether to buy any stock: the score does not know your situation, and it is not a recommendation to buy or sell anything. Please do your own research.
IRD scores -1 today, which Breakaway calls Poor (below zero). That is #60 of 90 in Pharma by Quality Score. The score adds up the chart checks, the trend, the company's filed sales, its profits, the news, insider trades, and Congress trades. The section above lists the lines behind IRD's -1.
5 insiders sold $10.6M across 12 filings in the last 6 months. No open-market buys on record. The newest is George Magrath, Chief Executive Officer, who sold $110K on Nov 3. Every filing, with the scored weight, for Pro members.
Only on the public pages, which run at least 15 minutes behind. Pro members, and anyone on a guest pass, see real-time prices: the scanner refreshes every 15 seconds, and your watchlist every few seconds, pre-market and after hours included.
Insider and Congress trades, the chart, and the financials, in one score.
See it live, free until tomorrow morning. No account. No card. Then keep going with a free account.